Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moroxydine hydrochloride is a small-molecule, broad-spectrum antiviral agent primarily utilized in ophthalmic formulations to treat viral infections of the eye. It is a biguanide derivative that is believed to interfere with viral replication, although its precise molecular mechanism of action remains not fully characterized. In China, it is marketed as eye drops (morpholine guanidine hydrochloride eye drops) for the treatment of viral conjunctivitis and keratitis, which are frequently caused by adenoviruses or herpesviruses. While historically used for systemic viral infections like influenza, its modern clinical application is largely focused on topical ocular therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on moroxydine hydrochloride.